

Motao Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5563268/publications.pdf>

Version: 2024-02-01

15
papers

2,447
citations

758635

12
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

4931
citing authors

#	ARTICLE	IF	CITATIONS
1	A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. <i>Biomaterials</i> , 2014, 35, 2383-2390.	5.7	1,352
2	Physicochemical Properties Determine Nanomaterial Cellular Uptake, Transport, and Fate. <i>Accounts of Chemical Research</i> , 2013, 46, 622-631.	7.6	627
3	Applications of nanomaterials as vaccine adjuvants. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2761-2774.	1.4	109
4	Microbiota regulate innate immune signaling and protective immunity against cancer. <i>Cell Host and Microbe</i> , 2021, 29, 959-974.e7.	5.1	67
5	Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113974.	6.6	65
6	Cell-Penetrating Nanoparticles Activate the Inflammasome to Enhance Antibody Production by Targeting Microtubule-Associated Protein 1-Light Chain 3 for Degradation. <i>ACS Nano</i> , 2020, 14, 3703-3717.	7.3	55
7	A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma. <i>Biomaterials</i> , 2012, 33, 6147-6154.	5.7	40
8	Understanding the Particokinetics of Engineered Nanomaterials for Safe and Effective Therapeutic Applications. <i>Small</i> , 2013, 9, 1619-1634.	5.2	39
9	How can nanotechnology help membrane vesicle-based cancer immunotherapy development?. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 222-225.	1.4	22
10	Nanomedicine targets iron metabolism for cancer therapy. <i>Cancer Science</i> , 2022, 113, 828-837.	1.7	19
11	Use of Nanoformulation to Target Macrophages for Disease Treatment. <i>Advanced Functional Materials</i> , 2021, 31, 2104487.	7.8	17
12	Beclin 2 negatively regulates innate immune signaling and tumor development. <i>Journal of Clinical Investigation</i> , 2020, 130, 5349-5369.	3.9	16
13	BECN2 (beclin 2) Negatively Regulates Inflammasome Sensors Through ATG9A-Dependent but ATG16L1- and LC3-Independent Non-Canonical Autophagy. <i>Autophagy</i> , 2022, 18, 340-356.	4.3	13
14	BECN2 (beclin 2)-mediated non-canonical autophagy in innate immune signaling and tumor development. <i>Autophagy</i> , 2020, 16, 2310-2312.	4.3	6
15	The Role of Autophagy at the Nano/Bio Interface - Underlying Mechanisms and Therapeutic Potential in Cancer. <i>Precision Nanomedicine</i> , 2021, 4, .	0.4	0